Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukemia at first relapse

References

• Bradstock KF, Matthews JP, Lowenthal RM, . A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine. Blood 2005;105:481–488.
   PubMed Web of Science ®Google Scholar
• Fernandez H, Sun Z, Yao X, . Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009;361:1249–1259.
   PubMed Web of Science ®Google Scholar
• Lee JH, Joo YD, Kim H, . A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. Blood 2011;118:3832–3841.
   PubMed Web of Science ®Google Scholar
• Lowenberg B, Ossenkoppele G, van Putten W, . High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009;361:1235–1248.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Milligan D, Goldstone A, . The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. Br J Haematol 2009;145:318–332.
   PubMed Web of Science ®Google Scholar
• Breems DA, Van Putten WL, Huijgens PC, . Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 2005;23:1969–1978.
   PubMed Web of Science ®Google Scholar
• Giles F, Verstovsek S, Garcia-Manero G, . Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse. Br J Haematol 2006;134:58–60.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Cortes J, Faderl S, . Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy. Blood 2010;116:5818–5823.
   PubMed Web of Science ®Google Scholar
• Chevallier P, Labopin M, Turlure P, . A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study. Leukemia 2011;25:939–944.
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Lee SJ, Advani R, . Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol 2004;22:1078–1086.
   PubMed Web of Science ®Google Scholar
• Parker J, Pagliuca A, Mijovic A, . Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol 1997;99:939–944.
   PubMed Web of Science ®Google Scholar
• Virchis A, Koh M, Rankin P, . Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes. Br J Haematol 2004;124:26–32.
   PubMed Web of Science ®Google Scholar
• Pastore D, Specchia G, Carluccio P, . FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience. Ann Hematol 2003;82:231–235.
   PubMed Web of Science ®Google Scholar
• Yavuz S, Paydas S, Disel U, . IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience. Am J Ther 2006;13:389–393.
   PubMedGoogle Scholar
• Price SL, Lancet JE, George TJ, . Salvage chemotherapy regimens for acute myeloid leukemia: is one better? Efficacy comparison between CLAG and MEC regimens. Leuk Res 2011;35:301–304.
   Google Scholar
• Litzow MR, Othus M, Cripe LD, . Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group. Br J Haematol 2010;148:217–225.
   PubMed Web of Science ®Google Scholar
• Levis M, Ravandi F, Wang ES, . Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood 2011;117:3294–3301.
   PubMed Web of Science ®Google Scholar
• Wierzbowska A, Robak T, Pluta A, . Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group. Eur J Haematol 2008;80:115–126.
   PubMed Web of Science ®Google Scholar
• Schmid C, Schleuning M, Schwerdtfeger R, . Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 2006;108:1092–1099.
   PubMed Web of Science ®Google Scholar
• Schmid C, Schleuning M, Ledderose G, . Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005;23:5675–5687.
   PubMed Web of Science ®Google Scholar
• Tauro S, Shankaranarayana P, Nitu-Whalley IC, . Stem cell transplantation after salvage therapy with high-dose cytarabine and amsacrine in adults with high-risk leukaemia. Bone Marrow Transplant 2003;32:273–278.
   PubMed Web of Science ®Google Scholar
• Tavernier E, Le QH, Elhamri M, . Salvage therapy in refractory acute myeloid leukemia: prediction of outcome based on analysis of prognostic factors. Leuk Res 2003;27:205–214.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Kopecky KJ, . Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003;21:4642–4649.
   PubMed Web of Science ®Google Scholar
• Dohner H, Estey EH, Amadori S, . Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115:453–474.
   PubMed Web of Science ®Google Scholar
• Grimwade D, Hills RK, Moorman AV, . Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010;116:354–365.
   PubMed Web of Science ®Google Scholar
• Leopold LH, Willemze R. The treatment of acute myeloid leukemia in first relapse: a comprehensive review of the literature. Leuk Lymphoma 2002;43:1715–1727.
   PubMed Web of Science ®Google Scholar
• Robak T. Purine nucleoside analogues in the treatment of myleoid leukemias. Leuk Lymphoma 2003;44:391–409.
   PubMed Web of Science ®Google Scholar
• Visani G, Tosi P, Zinzani PL, . FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of “poor risk” acute myeloid leukemias. Leukemia 1994;8:1842–1846.
   PubMed Web of Science ®Google Scholar
• Tosi P, Visani G, Ottaviani E, . Fludarabine + Ara-C + G-CSF: cytotoxic effect and induction of apoptosis on fresh acute myeloid leukemia cells. Leukemia 1994;8:2076–2082.
   PubMed Web of Science ®Google Scholar
• Gandhi V, Estey E, Du M, . Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia. Clin Cancer Res 1995; 1:169–178.
   PubMed Web of Science ®Google Scholar
• te Boekhorst PA, Lowenberg B, Sonneveld P. Hematopoietic growth factor stimulation and cytarabine cytotoxicity in vitro: effects in untreated and relapsed or primary refractory acute myeloid leukemia cells. Leukemia 1994;8:1480–1486.
   PubMed Web of Science ®Google Scholar
• Estey E, Thall P, Andreeff M, . Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 1994;12:671–678.
   PubMed Web of Science ®Google Scholar
• Schmid C, Schleuning M, Tischer J, . Early allo-SCT for AML with a complex aberrant karyotype—results from a prospective pilot study. Bone Marrow Transplant 2012;47:46–53.
   PubMed Web of Science ®Google Scholar
• Arellano ML, Langston A, Winton E, . Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience. Biol Blood Marrow Transplant 2007;13:116–123.
   PubMed Web of Science ®Google Scholar
• Ferrara F, Morabito F, Latagliata R, . Aggressive salvage treatment is not appropriate for the majority of elderly patients with acute myeloid leukemia relapsed from first complete remission. Haematologica 2001;86:814–820.
   PubMed Web of Science ®Google Scholar
• Arlin ZA, Feldman EJ, Mittelman A, . Amsacrine is safe and effective therapy for patients with myocardial dysfunction and acute leukemia. Cancer 1991;68:1198–1200.
   PubMed Web of Science ®Google Scholar
• Kessler T, Mohr M, Müller-Tidow C, . Amsacrine containing induction therapy in elderly AML patients: comparison to standard induction regimens in a matched-pair analysis. Leuk Res 2008;32: 491–494.
   PubMed Web of Science ®Google Scholar